June 24, 2011

Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

Free full text available for several days only. 

This industry-sponsored phase 2 RCT examined the impact of  bardoxolone methyl, an oral antioxidant inflammation modulator, on renal function in patients with CKD and diabetes.  At 24 and 52 weeks, the intervention arms had improved eGFR compared to placebo.  Hard clinical endpoints were not examined in this study.

Related Articles:

Chronic Kidney Disease, Diabetes

Comments are closed.